Novel views on new-onset diabetes after transplantation: development, prevention and treatment
Open accessThe DOI matches its Crossref record; 183 of the 187 references it cites were found in a registry or an index.
Abstract
New-onset diabetes after transplantation (NODAT) is associated with increased risk of allograft failure, cardiovascular disease and mortality, and therefore, jeopardizes the success of renal transplantation. Increased awareness of NODAT and the prediabetic states (impaired fasting glucose and impaired glucose tolerance, IGT) has fostered previous and present recommendations, based on the management of type 2 diabetes mellitus (T2DM). Unfortunately, the idea that NODAT merely resembles T2DM is potentially misleading, because the opportunity to initiate adequate anti-hyperglycaemic treatment early after transplantation might be given away for 'tailored' immunosuppression in patients who have developed NODAT or carry personal risk factors. Risk factor-independent mechanisms, however, seem to render postoperative hyperglycaemia with subsequent development of overt or 'full-blown' NODAT, the unavoidable consequence of the transplant and immunosuppressive process itself, at least in many cases. A proof of the concept that timely preventive intervention with exogenous insulin against post-transplant hyperglycaemia may decrease NODAT was recently provided by a small clinical trial, which is awaiting confirmation from a multicentre study. However, because early insulin therapy aimed at beta-cell protection seems to contrast the currently recommended, stepwise approach of 'watchful waiting' prior to pancreatic decompensation, we here aim at reviewing recent concepts regarding the development, prevention and treatment of NODAT, some of which seem to challenge the traditional view on T2DM and NODAT. In summary, we suggest a novel, risk factor-independent management approach to NODAT, which includes glycaemic monitoring and anti-hyperglycaemic treatment in virtually everybody after transplantation. This approach has widespread implications for future research and is intended to tackle NODAT and also ultimately cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The OGTT is considered the goldstandard test for the diagnosis of PTDM (1 year posttransplant) (138,139,148,149).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Hyperglycemia is very common during the early posttransplant period, with 90% of kidney allograft recipients exhibiting hyperglycemia in the fi rst few weeks following transplant (138,139,141,142).”
From 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2024 (2024) · cites this paper as [139]
The cited source says what the claim attributes to it.
In the citing paper
“Hyperglycemia is very common during the early posttransplant period, with 90% of kidney allograft recipients exhibiting hyperglycemia in the first few weeks following transplant (138,139,141,142).”
From 2. Diagnosis and classification of diabetes: standards of care in diabetes-2025 (2025) · cites this paper as [139]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2011) · Diabetes Care · doi:10.2337/dc11-s062 · Cited by 13,988
Lee, I.-M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., & Katzmarzyk, P. T. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61031-9 · Cited by 8,215
Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y. C., Held, P. J., & Port, F. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912023412303 · Cited by 5,371
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Sugar-Sweetened Beverages and Risk of Metabolic Syndrome and Type 2 Diabetes
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., Willett, W. C., & Hu, F. B. (2010) · Diabetes Care · doi:10.2337/dc10-1079 · Cited by 2,116
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940 · cited 1×
“These distinctions imply different physiological interpretations, although it may not be trivial to make inferences about treatment for T2DM, as a consequence of further untangling this puzzling relationship [131].”
BackgroundU.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Sugar-Sweetened Beverages, Obesity, Type 2 Diabetes Mellitus, and Cardiovascular Disease Risk
Malik, V. S., Popkin, B. M., Bray, G. A., Després, J.-P., & Hu, F. B. (2010) · Circulation · doi:10.1161/circulationaha.109.876185 · Cited by 1,641
Immunosuppressive Drugs for Kidney Transplantation
Halloran, P. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra033540 · Cited by 1,555
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2012) · Diabetes Care · doi:10.2337/dc12-s064 · Cited by 1,491
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 1×
“Because insulin secretion is tightly regulated by insulin sensitivity [128], the matter of query is also about the type of relationship between the two entities.”
BackgroundPereira, M. A., Kartashov, A. I., Ebbeling, C. B., Van Horn, L., Slattery, M. L., Jacobs, D. R., & Ludwig, D. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17663-0 · Cited by 1,348
Buchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Diabetes Mellitus after Kidney Transplantation in the United States
Kasiske, B. L., Snyder, J. J., Gilbertson, D., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,285
Management of diabetes and hyperglycemia in hospitals.
Clement, S., Braithwaite, S. S., Magee, M. F., Ahmann, A., Smith, E. P., Schafer, R. G., Hirsch, I. B., & on behalf of the Diabetes in Hospitals Writing Committee (2004) · Diabetes Care · doi:10.2337/diacare.27.2.553 · Cited by 1,266 · cited 1×
“This vicious cycle of hyperglycaemia and hypoinsulinaemia has been reported to be associated with poor hospital outcomes [109], and most likely occurs in an accelerated form during the course of NODAT development.”
BackgroundTumor necrosis factor alpha inhibits signaling from the insulin receptor.
Hotamisligil, G. S., Murray, D. L., Choy, L. N., & Spiegelman, B. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.4854 · Cited by 1,199
Pirsch, J. D., Miller, J., Deierhoi, M. H., Vincenti, F., & Filo, R. S. (1997) · Transplantation · doi:10.1097/00007890-199704150-00013 · Cited by 1,122
Use of metabolic markers to identify overweight individuals who are insulin resistant
McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00007 · Cited by 1,022
Clinical risk factors, DNA variants, and the development of type 2 diabetes
Lyssenko, V., Jonsson, A., Almgren, P., Pulizzi, N., Isomaa, B., Tuomi, T., Berglund, G., Altshuler, D., Nilsson, P., & Groop, L. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801869 · Cited by 938
OJO, A. O., HANSON, J. A., MEIER-KRIESCHE, H.-U., OKECHUKWU, C. N., WOLFE, R. A., LEICHTMAN, A. B., AGODOA, L. Y., KAPLAN, B., & PORT, F. K. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123589 · Cited by 879
Weng, J., Li, Y., Xu, W., Shi, L., Zhang, Q., Zhu, D., Hu, Y., Zhou, Z., Yan, X., Tian, H., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60762-x · Cited by 780
Dietary fats and prevention of type 2 diabetes
Risérus, U., Willett, W. C., & Hu, F. B. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.10.002 · Cited by 753
Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006) · Diabetes Care · doi:10.2337/dc05-2179 · Cited by 744 · cited 1×
“Eventually, beta-cell failure is responsible for IGT progression to T2DM [123, 124]; among IGT subjects, a low plasma insulin concentration predicts IGT progression to T2DM in many ethnic groups [125, 126].”
BackgroundPoitout, V., & Robertson, R. P. (2002) · Endocrinology · doi:10.1210/endo.143.2.8623 · Cited by 743 · cited 1×
“Beta-cell failure appears to play a major role in T2DM development [91, 92] and is thus very likely to play a key role in NODAT development as well.”
BackgroundDeceased-Donor Characteristics and the Survival Benefit of Kidney Transplantation
Merion, R. M. (2005) · JAMA · doi:10.1001/jama.294.21.2726 · Cited by 739
Mayer, A. D., Dmitrewski, J., Squifflet, J.-P., Besse, T., Grabensee, B., Klein, B., Eigler, F. W., Heemann, U., Pichlmayr, R., Behrend, M., et al. (1997) · Transplantation · doi:10.1097/00007890-199708150-00012 · Cited by 724
β-Cell Failure in Diabetes and Preservation by Clinical Treatment
Wajchenberg, B. L. (2007) · Endocrine Reviews · doi:10.1210/10.1210/er.2006-0038 · Cited by 714
Effect of waiting time on renal transplant outcome
Meier-Kriesche, H.-U., Port, F. K., Ojo, A. O., Rudich, S. M., Hanson, J. A., Cibrik, D. M., Leichtman, A. B., & Kaplan, B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00287.x · Cited by 687
NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1
Davidson, J., Wilkinson, A., Dantal, J., Dotta, F., Haller, H., Hernandez, D., Kasiske, B. L., Kiberd, B., Krentz, A., Legendre, C., et al. (2003) · Transplantation · doi:10.1097/01.tp.0000069952.49242.3e · Cited by 676
The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.9.7713 · Cited by 660
White rice consumption and risk of type 2 diabetes: meta-analysis and systematic review
Hu, E. A., Pan, A., Malik, V., & Sun, Q. (2012) · BMJ · doi:10.1136/bmj.e1454 · Cited by 631 · cited 1×
“(b) Common but unhealthy dietary habits, for example excessive consumption of pure sugar, rapidly absorbed carbohydrates and saturated fatty acids (‘fast food’), in conjunction with a deficiency of aerobic exercise, are well known to increase the risk of developing T2DM [98–103] and are, therefore, very likely to also…”
BackgroundVincenti, F., Friman, S., Scheuermann, E., Rostaing, L., Jenssen, T., Campistol, J. M., Uchida, K., Pescovitz, M. D., Marchetti, P., Tuncer, M., et al. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01749.x · Cited by 619
Dose-related patterns of glucocorticoid-induced side effects
Huscher, D., Thiele, K., Gromnica-Ihle, E., Hein, G., Demary, W., Dreher, R., Zink, A., & Buttgereit, F. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.092163 · Cited by 604 · cited 1×
“(ii) Glucocorticoids increase dose-related [75] hepatic glucose production (via stimulation of gluconeogenesis), augment insulin resistance [76–79] and suppress insulin secretion, in addition to inducing islet cell apoptosis at higher doses [80–86].”
BackgroundPolonsky, K. S., Sturis, J., & Bell, G. I. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341207 · Cited by 595
Immunosuppression: Evolution in Practice and Trends, 1994–2004
Meier-Kriesche, H.-U., Li, S., Gruessner, R. W. G., Fung, J. J., Bustami, R. T., Barr, M. L., & Leichtman, A. B. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01270.x · Cited by 559
Lang, C. H., Dobrescu, C., & Bagby, G. J. (1992) · Endocrinology · doi:10.1210/endo.130.1.1727716 · Cited by 535
Ihara, Y., Toyokuni, S., Uchida, K., Odaka, H., Tanaka, T., Ikeda, H., Hiai, H., Seino, Y., & Yamada, Y. (1999) · Diabetes · doi:10.2337/diabetes.48.4.927 · Cited by 506
Woodle, E. S., First, M. R., Pirsch, J., Shihab, F., Gaber, A. O., & Van Veldhuisen, P. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318187d1da · Cited by 474
Immunosuppressive strategies in transplantation
Denton, M. D., Magee, C. C., & Sayegh, M. H. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07493-5 · Cited by 449
Mu, J., Woods, J., Zhou, Y.-P., Roy, R. S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A. D., et al. (2006) · Diabetes · doi:10.2337/db05-1602 · Cited by 449
Calcineurin/NFAT signalling regulates pancreatic β-cell growth and function
Heit, J. J., Apelqvist, Å. A., Gu, X., Winslow, M. M., Neilson, J. R., Crabtree, G. R., & Kim, S. K. (2006) · Nature · doi:10.1038/nature05097 · Cited by 444
Mechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Patient survival after renal transplantation: IV. Impact of post-transplant diabetes
Cosio, F. G., Pesavento, T. E., Kim, S., Osei, K., Henry, M., & Ferguson, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00582.x · Cited by 422
Lambillotte, C., Gilon, P., & Henquin, J. C. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119175 · Cited by 419 · cited 1×
“(ii) Glucocorticoids increase dose-related [75] hepatic glucose production (via stimulation of gluconeogenesis), augment insulin resistance [76–79] and suppress insulin secretion, in addition to inducing islet cell apoptosis at higher doses [80–86].”
BackgroundWoodward, R. S., Schnitzler, M. A., Baty, J., Lowell, J. A., Lopez-Rocafort, L., Haider, S., Woodworth, T. G., & Brennane, D. C. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00082.x · Cited by 402
Cosio, F. G., Pesavento, T. E., Osei, K., Henry, M. L., & Ferguson, R. M. (2001) · Kidney International · doi:10.1046/j.1523-1755.2001.059002732.x · Cited by 381
Glucose Induces β-Cell Apoptosis Via Upregulation of the Fas Receptor in Human Islets
Maedler, K., Spinas, G. A., Lehmann, R., Sergeev, P., Weber, M., Fontana, A., Kaiser, N., & Donath, M. Y. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1683 · Cited by 367
Hjelmesæth, J., Hartmann, A., Leivestad, T., Holdaas, H., Sagedal, S., Olstad, M., & Jenssen, T. (2006) · Kidney International · doi:10.1038/sj.ki.5000116 · Cited by 345
High Glucose Causes Apoptosis in Cultured Human Pancreatic Islets of Langerhans
Federici, M., Hribal, M., Perego, L., Ranalli, M., Caradonna, Z., Perego, C., Usellini, L., Nano, R., Bonini, P., Bertuzzi, F., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.6.1290 · Cited by 333
Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids.
Delaunay, F., Khan, A., Cintra, A., Davani, B., Ling, Z. C., Andersson, A., Ostenson, C. G., Gustafsson, J., Efendic, S., & Okret, S. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119743 · Cited by 333
Becker, B., Kronenberg, F., Kielstein, J. T., Haller, H., Morath, C., Ritz, E., & Fliser, D. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2004090742 · Cited by 329
Li, Y., Xu, W., Liao, Z., Yao, B., Chen, X., Huang, Z., Hu, G., & Weng, J. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2597 · Cited by 323
RABBAT, C. G., THORPE, K. E., RUSSELL, J. D., & CHURCHILL, D. N. (2000) · Journal of the American Society of Nephrology · doi:10.1681/asn.v115917 · Cited by 312
The renal metabolism of insulin
Rabkin, R., Ryan, M. P., & Duckworth, W. C. (1984) · Diabetologia · doi:10.1007/bf00304849 · Cited by 295
Type 2 (non-insulin-dependent) diabetes ? An epidemiological overview
Zimmet, P. (1982) · Diabetologia · doi:10.1007/bf00282581 · Cited by 278
Olefsky, J. M. (1975) · Journal of Clinical Investigation · doi:10.1172/jci108231 · Cited by 277 · cited 1×
“(ii) Glucocorticoids increase dose-related [75] hepatic glucose production (via stimulation of gluconeogenesis), augment insulin resistance [76–79] and suppress insulin secretion, in addition to inducing islet cell apoptosis at higher doses [80–86].”
BackgroundIlkova, H., Glaser, B., Tunçkale, A., Bagriaçik, N., & Cerasi, E. (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1353 · Cited by 269 · cited 1×
“In the general population, the benefit of insulin therapy for long-term glycaemic control among newly diagnosed type 2 diabetic patients has been reported from 1997 onwards [154–158].”
BackgroundBeta cell function and its relation to insulin action in humans: a critical appraisal
Ferrannini, E., & Mari, A. (2004) · Diabetologia · doi:10.1007/s00125-004-1381-z · Cited by 262
Steroid avoidance or withdrawal for kidney transplant recipients
Haller, M. C., Royuela, A., Nagler, E. V., Pascual, J., & Webster, A. C. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005632.pub3 · Cited by 258
Changes in quality of life after renal transplantation
Jofre, R., Lopez-Gomez, J., Moreno, F., Sanz-Guajardo, D., & Valderrabano, F. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9669429 · Cited by 254
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70146-5 · Cited by 252
New onset diabetes after transplantation (NODAT): an overview
Pham, P.-T., Pham, P.-M., & Pham, P.-C. (2011) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s19027 · Cited by 243
Short-Term Intensive Insulin Therapy in Newly Diagnosed Type 2 Diabetes
Ryan, E. A., Imes, S., & Wallace, C. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1028 · Cited by 241
A two-step model for development of non-insulin-dependent diabetes
Saad, M. F., Knowler, W. C., Pettitt, D. J., Nelson, R. G., Charles, M. A., & Bennett, P. H. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80165-i · Cited by 234
The Importance of -Cell Failure in the Development and Progression of Type 2 Diabetes
Kahn, S. E. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.9.4047 · Cited by 232
Hjelmes�th, J., Sagedal, S., Hartmann, A., Rollag, H., Egeland, T., Hagen, M., Nordal, K. P., & Jenssen, T. (2004) · Diabetologia · doi:10.1007/s00125-004-1499-z · Cited by 228
Impact of Acute Rejection and New-Onset Diabetes on Long-Term Transplant Graft and Patient Survival
Cole, E. H., Johnston, O., Rose, C. L., & Gill, J. S. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04681107 · Cited by 226
Early Basal Insulin Therapy Decreases New-Onset Diabetes after Renal Transplantation
Hecking, M., Haidinger, M., Döller, D., Werzowa, J., Tura, A., Zhang, J., Tekoglu, H., Pleiner, J., Wrba, T., Rasoul-Rockenschaub, S., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011080835 · Cited by 226
New-onset diabetes after transplantation
Marchetti, P. (2004) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2004.03.007 · Cited by 221
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215
Ichinose, K., Maeshima, Y., Yamamoto, Y., Kinomura, M., Hirokoshi, K., Kitayama, H., Takazawa, Y., Sugiyama, H., Yamasaki, Y., Agata, N., et al. (2006) · Diabetes · doi:10.2337/db05-1367 · Cited by 215
Redmon, J. B., Olson, L. K., Armstrong, M. B., Greene, M. J., & Robertson, R. P. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119105 · Cited by 204
Transplantation — A Medical Miracle of the 20th Century
Morris, P. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048256 · Cited by 204
Renin-angiotensin system inhibition prevents type 2 diabetes mellitus
Scheen, A. (2004) · Diabetes & Metabolism · doi:10.1016/s1262-3636(07)70147-7 · Cited by 197
Dexamethasone Induces Cell Death in Insulin-Secreting Cells, an Effect Reversed by Exendin-4
Ranta, F., Avram, D., Berchtold, S., Düfer, M., Drews, G., Lang, F., & Ullrich, S. (2006) · Diabetes · doi:10.2337/db05-1220 · Cited by 195
Kamar, N., Toupance, O., Buchler, M., Sandres-Saune, K., Izopet, J., Durand, D., & Rostaing, L. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000079613.81511.3c · Cited by 187
Ullrich, S., Berchtold, S., Ranta, F., Seebohm, G., Henke, G., Lupescu, A., Mack, A. F., Chao, C.-M., Su, J., Nitschke, R., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.4.1090 · Cited by 176
Western-Style Fast Food Intake and Cardiometabolic Risk in an Eastern Country
Odegaard, A. O., Koh, W. P., Yuan, J.-M., Gross, M. D., & Pereira, M. A. (2012) · Circulation · doi:10.1161/circulationaha.111.084004 · Cited by 173
Nam, J. H., Mun, J. I., Kim, S. I., Kang, S. W., Choi, K. H., Park, K., Ahn, C. W., Cha, B. S., Song, Y. D., Lim, S. K., et al. (2001) · Transplantation · doi:10.1097/00007890-200105270-00011 · Cited by 163
Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis
Naing, C. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i14.1642 · Cited by 163
The association of early post-transplant glucose levels with long-term mortality
Valderhaug, T. G., Hjelmesæth, J., Hartmann, A., Røislien, J., Bergrem, H. A., Leivestad, T., Line, P. D., & Jenssen, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2105-9 · Cited by 163
Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism
Qi, D., & Rodrigues, B. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00453.2006 · Cited by 162
The Burden of Chronic Kidney Disease in Renal Transplant Recipients
Karthikeyan, V., Karpinski, J., Nair, R. C., & Knoll, G. A. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00315.x · Cited by 158
Luan, F. L., Steffick, D., & OJO, A. O. (2011) · Transplantation · doi:10.1097/tp.0b013e318203c25f · Cited by 156
Olefsky, J. M., Johnson, J. W., Liu, F., Jen, P., & Reaven, G. M. (1975) · Metabolism · doi:10.1016/0026-0495(75)90076-1 · Cited by 149
Krishnan, S., Rosenberg, L., & Palmer, J. R. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn344 · Cited by 149 · cited 1×
“(c) Physical inactivity is an inevitable consequence of early postoperative rehabilitation, but simultaneously a major contributor to T2DM [104, 105].”
BackgroundNew-Onset Diabetes After Kidney Transplantation—Changes and Challenges
Yates, C. J., Fourlanos, S., Hjelmesæth, J., Colman, P. G., & Cohney, S. J. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03855.x · Cited by 147
Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
DeFronzo, R. A., & Abdul-Ghani, M. (2011) · Diabetes Care · doi:10.2337/dc11-s221 · Cited by 147
Magnuson, M. A., Quinn, P. G., & Granner, D. K. (1987) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48115-x · Cited by 145
INSULIN RESISTANCE AND INSULIN DEFICIENCY IN THE PATHOGENESIS OF POSTTRANSPLANTATION DIABETES IN MAN
EKSTRAND, A. V., ERIKSSON, J. G., GRÖNHAGEN-RISKA, C., AHONEN, P. J., & GROOP, L. C. (1992) · Transplantation · doi:10.1097/00007890-199203000-00014 · Cited by 145
Van Laecke, S., Van Biesen, W., Verbeke, F., De Bacquer, D., Peeters, P., & Vanholder, R. (2009) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2009.02752.x · Cited by 145
Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia
Sharif, A., Moore, R., & Baboolal, K. (2008) · Transplantation · doi:10.1097/tp.0b013e3181605ebf · Cited by 144 · cited 14×
“Increased awareness of NODAT and the prediabetic states (impaired fasting glucose and impaired glucose tolerance, IGT) has fostered previous and present recommendations, based on the management of type 2 diabetes mellitus (T2DM).”
BackgroundInfluentialSelf-citationDUIJNHOVEN, E. M. V., BOOTS, J. M. M., CHRISTIAANS, M. H. L., WOLFFENBUTTEL, B. H. R., & HOOFF, J. P. V. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v123583 · Cited by 139
THE SYNDROME OF DIABETES MELLITUS AND ITS CAUSES*1
Himsworth, H. P. (1949) · The Lancet · doi:10.1016/s0140-6736(49)90797-7 · Cited by 132
Perioperative Glucose Control in the Diabetic or Nondiabetic Patient
Smiley, D. D., & Umpierrez, G. E. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000209366.91803.99 · Cited by 129
A Systematic Review on Steroid Withdrawal Between 3 and 6 Months After Kidney Transplantation
Pascual, J., Galeano, C., Royuela, A., & Zamora, J. (2010) · Transplantation · doi:10.1097/tp.0b013e3181e58912 · Cited by 127
Changes in Quality of Life After Renal Transplantation
Overbeck, I., Bartels, M., Decker, O., Harms, J., Hauss, J., & Fangmann, J. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.09.019 · Cited by 125
Hyperglycemia during the immediate period after kidney transplantation
Chakkera, H. A., Weil, E. J., Castro, J., Heilman, R. L., Reddy, K. S., Mazur, M. J., Hamawi, K., Mulligan, D. C., Moss, A. A., Mekeel, K. L., et al. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05471008 · Cited by 124
Evaluating mechanisms of post-transplant diabetes mellitus
van Hooff, J. P. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1063 · Cited by 116
Diabetes Mellitus: Its differentiation into insulin-sensitive and insulin-insensitive types
Himsworth, H. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt203 · Cited by 112
Pascual, J., Royuela, A., Galeano, C., Crespo, M., & Zamora, J. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr374 · Cited by 112
McFarlane, S. I., Chaiken, R. L., Hirsch, S., Harrington, P., Lebovitz, H. E., & Banerji, M. A. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00395.x · Cited by 111
Beard, J. C., Halter, J. B., Best, J. D., Pfeifer, M. A., & Porte, D. (1984) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1984.247.5.e592 · Cited by 109
Targeting β-Cell Function Early in the Course of Therapy for Type 2 Diabetes Mellitus
Leahy, J. L., Hirsch, I. B., Peterson, K. A., & Schneider, D. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0668 · Cited by 108
Hagen, M. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg338 · Cited by 106
Emre, S., Genyk, Y., Schluger, L. K., Fishbein, T., Guy, S. R., Sheiner, P. A., Schwartz, M., & Miller, C. M. (2000) · Transplant International · doi:10.1111/j.1432-2277.2000.tb01040.x · Cited by 106
Chakkera, H. A., Knowler, W. C., Devarapalli, Y., Weil, E. J., Heilman, R. L., Dueck, A., Mulligan, D. C., Reddy, K. S., Moss, A. A., Mekeel, K. L., et al. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09481209 · Cited by 105
DIABETES MANAGEMENT IN SPECIAL SITUATIONS
Hirsch, I. B., & Paauw, D. S. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70271-1 · Cited by 101
Polycystic Kidney Disease Is a Risk Factor for New-Onset Diabetes After Transplantation
Hamer, R. A., Chow, C. L., Ong, A. C. M., & McKane, W. S. (2007) · Transplantation · doi:10.1097/01.tp.0000248759.37146.3d · Cited by 100
Repaglinide in the Management of New-Onset Diabetes Mellitus After Renal Transplantation
Türk, T., Pietruck, F., Dolff, S., Kribben, A., Janssen, O. E., Mann, K., Philipp, T., Heemann, U., & Witzke, O. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01250.x · Cited by 98
Pioglitazone in the Management of Diabetes Mellitus after Transplantation
Luther, P., & Baldwin, D. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00613.x · Cited by 91
de Mattos, A. M., Olyaei, A. J., Prather, J. C., Golconda, M. S., Barry, J. M., & Norman, D. J. (2005) · Kidney International · doi:10.1111/j.1523-1755.2005.67132.x · Cited by 89
Complications associated with new-onset diabetes after kidney transplantation
Sharif, A., & Baboolal, K. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.174 · Cited by 89
Transplant-Associated Hyperglycemia: A New Look at an Old Problem
Crutchlow, M. F., & Bloom, R. D. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03671106 · Cited by 88
Werzowa, J., Hecking, M., Haidinger, M., Lechner, F., Döller, D., Pacini, G., Stemer, G., Pleiner, J., Frantal, S., & Säemann, M. D. (2013) · Transplantation · doi:10.1097/tp.0b013e318276a20e · Cited by 87
Self-citationAssociation of Metabolic Syndrome With Development of New-Onset Diabetes After Transplantation
Bayer, N. D., Cochetti, P. T., Anil Kumar, M. S., Teal, V., Huan, Y., Doria, C., Bloom, R. D., & Rosas, S. E. (2010) · Transplantation · doi:10.1097/tp.0b013e3181f1543c · Cited by 86
Sitagliptin Therapy in Kidney Transplant Recipients With New-Onset Diabetes After Transplantation
Lane, J. T., Odegaard, D. E., Haire, C. E., Collier, D. S., Wrenshall, L. E., & Stevens, R. B. (2011) · Transplantation · doi:10.1097/tp.0b013e3182347ea4 · Cited by 79
TCF7L2 Polymorphism Associates with New-Onset Diabetes after Transplantation
Ghisdal, L., Baron, C., Meur, Y. L., Lionet, A., Halimi, J., Rérolle, J.-P., Glowacki, F., Lebranchu, Y., Drouet, M., Noël, C., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121314 · Cited by 79
HOSPITAL MANAGEMENT OF DIABETES
Levetan, C. S., & Magee, M. F. (2000) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70162-6 · Cited by 78
Eurotransplant kidney allocation system (ETKAS): rationale and implementation
Mayer, G. J., & Persijn, G. G. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi269 · Cited by 77
Steroid Sparing in Kidney Transplantation
Augustine, J. J., & Hricik, D. E. (2006) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01800506 · Cited by 76
Hjelmesæth, J., Müller, F., Jenssen, T., Rollag, H., Sagedal, S., & Hartmann, A. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfi033 · Cited by 76
Ghisdal, L., Bouchta, N. B., Broeders, N., Crenier, L., Hoang, A.-D., Abramowicz, D., & Wissing, K. M. (2007) · Transplant International · doi:10.1111/j.1432-2277.2007.00589.x · Cited by 76
New-Onset Diabetes After Kidney Transplantation: Prevalence, Risk Factors, and Management
Sarno, G., Muscogiuri, G., & Rosa, P. D. (2012) · Transplantation · doi:10.1097/tp.0b013e31824db97d · Cited by 75
New-Onset Diabetes Mellitus in the Kidney Recipient: Diagnosis and Management Strategies
Bloom, R. D., & Crutchlow, M. F. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02650707 · Cited by 74
Porrini, E., Delgado, P., Alvarez, A., Cobo, M., Perez, L., Gonzalez-Posada, J. M., Hortal, L., Gallego, R., Garcia, J. J., Checa, M., et al. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm762 · Cited by 74
Kurian, B., Joshi, R., & Helmuth, A. (2008) · Endocrine Practice · doi:10.4158/ep.14.8.979 · Cited by 73
Aspects of quality of life through end-stage renal disease
Franke, G. H., Reimer, J., Philipp, T., & Heemann, U. W. (2003) · Quality of Life Research · doi:10.1023/a:1022238707028 · Cited by 73
Goals of Treatment for Type 2 Diabetes
Marchetti, P., Lupi, R., Guerra, S. D., Bugliani, M., D’Aleo, V., Occhipinti, M., Boggi, U., Marselli, L., & Masini, M. (2009) · Diabetes Care · doi:10.2337/dc09-s306 · Cited by 72
Diabetes mellitus: Its differentiation into insulin‐sensitive and insulin‐insensitive types*
Himsworth, H. P. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.3508.x · Cited by 71
Should Metformin Be Our Antiglycemic Agent of Choice Post-transplantation?
Sharif, A. (2011) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03550.x · Cited by 69
Rubenstein, A. H., Mako, M. E., & Horwitz, D. L. (1975) · Nephron · doi:10.1159/000180518 · Cited by 69
Midtvedt, K., Hartmann, A., Hjelmesaeth, J., Lund, K., & Bjerkely, B. L. (1998) · Nephrology Dialysis Transplantation · doi:10.1093/oxfordjournals.ndt.a027841 · Cited by 69
Polycystic kidney disease as a risk factor for post-transplant diabetes mellitus
Ducloux, D. (1999) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/14.5.1244 · Cited by 68
Luan, F. L., Steffick, D., Gadegbeku, C. A., Norman, S. P., Wolfe, R. A., & OJO, A. O. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02442.x · Cited by 67
DIETARY-PROTEIN RESTRICTION IN CHRONIC RENAL-FAILURE
Rosman, J. B., Sluiter, W. J., & Donker, A. (1985) · The Lancet · Cited by 67
Post-Transplant Diabetes Mellitus in Renal Allograft Recipients: A Matched-Pair Control Study
von Kiparski, A., Frei, D., Uhlschmid, G. K., Largiadèr, F., & BINSWANGER, U. (1990) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/5.3.220 · Cited by 66
Posttransplant Diabetes Mellitus and Acute Rejection: Impact on Kidney Transplant Outcome
Matas, A. J., Gillingham, K. J., Humar, A., Ibrahim, H. N., Payne, W. D., Gruessner, R. W. G., Dunn, T. B., Sutherland, D. E. R., Najarian, J. S., & Kandaswamy, R. (2008) · Transplantation · doi:10.1097/tp.0b013e318160ee42 · Cited by 64
Johnson, J. A., & Gale, E. A. M. (2010) · Diabetes · doi:10.2337/db10-0334 · Cited by 64
Khan, A., Ostenson, C. G., Berggren, P. O., & Efendic, S. (1992) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1992.263.4.e663 · Cited by 61
Wong, W., Venetz, J.-P., TOLKOFF-RUBIN, N. E., & Pascual, M. A. (2005) · Transplantation · doi:10.1097/01.tp.0000168436.76784.45 · Cited by 60
Qian, L., Xu, L., Wang, X., Fu, X., Gu, Y., Fan, L., Peng, Y., Li, G., & Luo, M. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.922 · Cited by 60
Valderhaug, T. G., Hjelmesæth, J., Jenssen, T., Røislien, J., Leivestad, T., & Hartmann, A. (2012) · Transplantation · doi:10.1097/tp.0b013e31825f4434 · Cited by 60
Prasad, G. V. R., Kim, S. J., Huang, M., Nash, M. M., Zaltzman, J. S., Fenton, S. S. A., Cattran, D. C., Cole, E. H., & Cardella, C. J. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2004.00598.x · Cited by 58
Hyperglycemia induces apoptosis and p53 mobilization to mitochondria in RINm5F cells
Ortega‐Camarillo, C., Guzmán‐Grenfell, A. M., García-Macedo, R., Rosales‐Torres, A. M., Ávalos‐Rodríguez, A., Durán-Reyes, G., Medina-Navarro, R., Cruz, M., Díaz-Flores, M., & Kumate, J. (2005) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-006-0829-5 · Cited by 56
Pietruck, F., Kribben, A., Van, T. N., Patschan, D., Herget-Rosenthal, S., Janssen, O., Mann, K., Philipp, T., & Witzke, O. (2005) · Transplant International · doi:10.1111/j.1432-2277.2004.00076.x · Cited by 54
Baxter-Jones, A., Helms, P., & Preece, M. (1994) · PubMed · Cited by 53
Baxter-Jones, A. D. G., Helms, P. J. B., Preece, M. A., Stone, P., Dann, T. C., & Roberts, D. F. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91261-0 · Cited by 53
Brunkhorst, R. R., Lufft, V., Dannenberg, B., Kliem, V., Tusch, G., & Pichlmayr, R. (2003) · Transplantation · doi:10.1097/01.tp.0000070225.38757.81 · Cited by 52
Siraj, E. S., Abacan, C., Chinnappa, P., Wojtowicz, J., & Braun, W. E. (2010) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.12.062 · Cited by 52
Neoral® rescue therapy in transplant patients with intolerance to tacrolimus
Abouljoud, M. S., Kumar, M. A., Brayman, K. L., Emre, S., Bynon, J., & for the OLN‐452 Study Group (2002) · Clinical Transplantation · doi:10.1034/j.1399-0012.2002.01054.x · Cited by 52
Mechanism of the Diabetogenic Action of Cyclosporin A
Menegazzo, L., Ursich, M. J. M., Fukui, R. T., Rocha, D. M., Silva, M. J., Ianhez, L. E., Sabbaga, E., & WAJCHENBERG, B. L. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978954 · Cited by 48
The hyperbolic equilibrium between insulin sensitivity and secretion
Pacini, G. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.10.014 · Cited by 47
Herold, K. C., Nagamatsu, S., Buse, J. B., KULSAKDINUN, P., & Steiner, D. F. (1993) · Transplantation · doi:10.1097/00007890-199301000-00035 · Cited by 46
Inhibition by corticosterone of calcium inflow and insulin release in rat pancreatic islets
Billaudel, B., Mathias, P. C. F., Sutter, B. C. J., & Malaisse, W. J. (1984) · Journal of Endocrinology · doi:10.1677/joe.0.1000227 · Cited by 44
Luan, F. L., Zhang, H., Schaubel, D. E., Miles, C. D., Cibrik, D., Norman, S., & Ojo, A. O. (2008) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2008.02328.x · Cited by 43
New-onset diabetes after transplantation: a threat to graft and patient survival
Krentz, A. J., & Wheeler, D. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17962-8 · Cited by 41
Cyclic AMP, Glucose and Cortisol in Plasma during Surgery
Madsen, S., Engquist, A., Badawi, I., & Kehlet, H. (1976) · Hormone and Metabolic Research · doi:10.1055/s-0028-1093601 · Cited by 40
Role of insulin resistance indices in predicting new-onset diabetes after kidney transplantation
Nagaraja, P., Ravindran, V. K., Morris‐Stiff, G. J., & Baboolal, K. (2012) · Transplant International · doi:10.1111/tri.12026 · Cited by 38
Pretransplant Evaluation of Renal Transplant Candidates
Gallon, L. G., Leventhal, J. R., & Kaufman, D. B. (2002) · Seminars in Nephrology · doi:10.1053/snep.2002.35966 · Cited by 37
Balaska, A., Moustafellos, P., Gourgiotis, S., Pistolas, D., Hadjiyannakis, E., Vougas, V., & Drakopoulos, S. (2006) · PubMed · Cited by 36
HIGH CARBOHYDRATE DIETS AND INSULIN EFFICIENCY
Himsworth, H. P. (1934) · BMJ · doi:10.1136/bmj.2.3836.57 · Cited by 36
Glucose tolerance before and after renal transplantation
Bergrem, H. A., Valderhaug, T. G., Hartmann, A., Bergrem, H., Hjelmesaeth, J. S., & Jenssen, T. G. (2009) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp566 · Cited by 35
The case for insulin treatment early in type 2 diabetes.
Palumbo, P. J. (2004) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.71.5.385 · Cited by 34
Gürsoy, M., Köksal, R., Karavelioğlu, D., Çolak, T., Gür, G., Özdemir, F. N., Boyacıoğlu, S., & Bi̇lgi̇n, N. (2000) · Transplantation Proceedings · doi:10.1016/s0041-1345(00)00898-8 · Cited by 31
Koizumi, M., & Yada, T. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0462 · Cited by 31
Oberholzer, J., Thielke, J., Hatipoglu, B., Testa, G., Sankary, H. N., & Benedetti, E. (2005) · Transplantation Proceedings · doi:10.1016/j.transproceed.2004.12.085 · Cited by 29 · cited 1×
“Specifically, pre-transplant individualization of immunosuppression based on cardiovascular and diabetes risk factors [32, 33, 38, 39, 60], and post-transplant withdrawal of corticosteroids or conversion from tacrolimus to cyclosporin A have been advocated [33] and described [139–143].”
BackgroundTransplant International Official Journal of the European Society for Organ Transplantation
(1992) · Springer eBooks · doi:10.1007/978-3-642-77423-2 · Cited by 28
The Allocation of Cadaver Kidneys for Transplantation in the United States
Neylan, J. F., Sayegh, M. H., Coffman, T. M., Danovitch, G. M., Krensky, A. M., Strom, T. B., Turka, L. A., & Harmon, W. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10102237 · Cited by 27
Posttransplantation diabetus mellitus under calcineurin inhibitor
Wyzgał, J., Oldakowska-Jedynak, U., Pączek, L., Michalska, M., Ziółkowski, J., Soluch, L., Zygier, D., Sańko-Resmer, J., Gradowska, L., Niewczas, M. A., et al. (2003) · Transplantation Proceedings · doi:10.1016/s0041-1345(03)00819-4 · Cited by 21
The islet in type 2 diabetes: back to center stage.
Cerasi, E., Boîtard, C., Efendić, S., Ferrannini, E., Henquin, J., & Steiner, D. F. (2001) · Diabetes · doi:10.2337/diabetes.50.2007.s1 · Cited by 20
Furuta, Y., Horiguchi, M., Sugaru, E., Ono‐Kishino, M., Otani, M., Sakai, M., Masui, Y., Tsuchida, A., Sato, Y., Takubo, K., et al. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01180.x · Cited by 19
Haidinger, M., Werzowa, J. M., Voigt, H.-C., Pleiner, J., Stemer, G., Hecking, M., Döller, D., Hörl, W. H., Weichhart, T., & Säemann, M. D. (2010) · Trials · doi:10.1186/1745-6215-11-91 · Cited by 18
Pietrzak-Nowacka, M., Safranow, K., Dziewanowski, K., Dębska-Ślizień, A. M., Głyda, M., Gołembiewska, E., Jankowska, M., Nowosiad, M., Rutkowski, B., & Ciechanowski, K. (2008) · PubMed · Cited by 13
SHIMIZU, M., Iino, Y., & Terashi, A. (1998) · Journal of Nippon Medical School · doi:10.1272/jnms1923.65.50 · Cited by 11
Clinical Trials for Treatment of NODAT
Sharif, A., de Vries, A. P. J., Porrini, E., Hecking, M., & Säemann, M. D. (2012) · Transplantation · doi:10.1097/tp.0b013e318260b1e9 · Cited by 10
Beta 2-adrenergic responsiveness in vivo during abdominal surgery
Ewaldsson, C. A., & Hahn, R. G. (1998) · British Journal of Anaesthesia · doi:10.1093/bja/81.3.343 · Cited by 7
Ensuring drug safety: lessons from the thiazolidinediones
Lancet, T. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61485-8 · Cited by 7
Transplant-Associated Hyperglycemia: Shedding Light on the Mechanisms
Reese, P. P., & Bloom, R. D. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01430210 · Cited by 6
Metformin Safety Posttransplantation—Trials and Tribulations
Sharif, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2011.03920.x · Cited by 4
Impaired Glucose Metabolism Despite Decreased Insulin Resistance After Renal Transplantation
Hecking, M., Kainz, A., Werzowa, J. M., Haidinger, M., Tura, A., Karaboyas, A., Hörl, W. H., Wolzt, M., Pacini, G., Port, F. K., et al. (2012) · Kidney Research and Clinical Practice · doi:10.1016/j.krcp.2012.04.399 · Cited by 3
Research works printed but not linked: 4
- 1984, American Journal of Physiology - Gastrointestinal and Liver Physiology, 247, E592
- 1992, American Journal of Physiology - Gastrointestinal and Liver Physiology, 263, E663
- Cerasi E. β-Cell dysfunction vs insulin resistance in type 2 diabetes: the eternal ‘chicken and egg’ question. Medicographia N° 106. 2011;33:35–41. [Google Scholar]
- Sharif A. Metformin safety post-transplantation—trials and tribulations. Am J Transplant. 2012;12:796. [Google Scholar]
Cited by
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s002 · Cited by 4,792
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s002 · Cited by 3,159
“No studies to date have established which noninsulin agents are safest or most efficacious in PTDM.”
BackgroundMethodInfluential2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s002 · Cited by 3,116
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Metadata
- Authors
- Hecking, M., Werzowa, J., Haidinger, M., Horl, W. H., Pascual, J., Budde, K., Luan, F. L., Ojo, A., de Vries, A. P. J., Porrini, E., Pacini, G., Port, F. K., Sharif, A., Saemann, M. D., & European-New-Onset Diabetes After Transplantation Working Group
- Affiliations
- Medical University of Vienna (AT)
- Hospital Del Mar (ES)
- Charité – Universitätsmedizin Berlin (DE)
- University of Michigan (US)
- Universidad de La Laguna (ES)
- National Research Council (IT)
- Arbor Research Collaborative for Health (US)
- Queen Elizabeth Hospital Birmingham (GB)
- Corresponding author
- Hecking, M.
- Venue
- Nephrology Dialysis Transplantation
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-01-17
- Volume
- 28
- Issue
- 3
- Pages
- 550-566
- ISSN
- 0931-0509 (ISSN-L)
- 1460-2385
- PMC
- PMC4375396
- OpenAlex
- W2164732183
- Cited by
- 120
- References
- 187
- Citations by year
- 2026: 4 · 2025: 2 · 2024: 8 · 2023: 8 · 2022: 11 · 2021: 8 · 2020: 7 · 2019: 8 · 2018: 11 · 2017: 9 · 2016: 10 · 2015: 18 · 2014: 10 · 2013: 6
- FWCI
- 10.71
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nephrology Dialysis Transplantation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K24DK062234)
- Topics
- Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Keywords
- post-transplant diabetes mellitus, kidney transplantation, type 2 diabetes, immunosuppression, impaired glucose tolerance, impaired fasting glucose, exogenous insulin therapy, beta-cell protection, glycaemic monitoring, allograft failure, cardiovascular disease
- MeSH terms
- Diabetes Mellitus, Type 2, Humans, Risk Factors, Organ Transplantation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.